



Perspective

Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines



Anthony T. Tan^a, Joey Ming Er Lim^a, Antonio Bertoletti^{a,b,*}

^a Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, 169857, Singapore

^b Singapore Immunology Network, A*STAR, Singapore, 138648, Singapore

How do we measure vaccine efficacy? The strictest but also easiest parameter to determine vaccine efficacy is its ability to block infection. Indeed, if a vaccine is able to block infection, this necessarily follows that it will also prevent both disease development and viral transmission. As a consequence, antibodies, specifically neutralising antibodies, have been used as the “gold standard” correlate of protection to measure SARS-CoV-2 vaccine efficacy, given their ability to block infection. Since SARS-CoV-2 infects cells by the binding of its spike protein to the host ACE-2 receptor, a vaccine that is able to induce a large quantity of antibodies able to block the interaction between the ACE-2 receptor and spike protein should theoretically be highly efficacious. Given this “antibody-centric” method of evaluating a vaccine, it is clear why spike mRNA vaccines have to date been regarded the most effective COVID-19 vaccine in the market.

The ability of spike mRNA vaccines to induce extremely high quantities of anti-spike antibodies is superior to all the other vaccine platforms (Zhang Z. et al., 2022), and is the reason why spike mRNA vaccines were initially highly efficacious in preventing symptomatic infection caused by the ancestral strain of SARS-CoV-2 (Thomas et al., 2021). On the contrary, inactivated SARS-CoV-2 vaccines (CoronaVac-Sinovac and BBIBP-CorV-Sinopharm), which were extensively distributed in 2021 and make up almost half of the 7.3 billion doses of SARS-CoV-2 vaccines used worldwide (Mallapaty, 2021), elicit a lower level of neutralising antibodies that wanes quickly (Lim et al., 2021; Peng et al., 2022; Zhang H. et al., 2022). This likely explains why inactivated SARS-CoV-2 vaccines are less effective in preventing symptomatic infection when compared to other vaccine platforms (Jara et al., 2021).

The epidemiological, virological, and immunological landscape of COVID-19 has evolved significantly since the onset of the pandemic in late 2019 (Van Dorp et al., 2021). In particular, the ancestral SARS-CoV-2 lineage has been substituted by diverging lineages with increasing number of mutations in the spike protein. These mutations render vaccine-induced antibodies less effective in neutralising emerging variants (Omicron lineages) (Liu L. et al., 2022). This has led to a shift in the perspective of what vaccination can and should protect a vaccinated

individual from: rather than focusing solely on the ability of a vaccine to prevent infection, we should instead evaluate it based on its efficacy in preventing severe disease.

Here, T cells play a significant role (Bertoletti et al., 2022). Indeed, while the primary role of antibodies is to prevent the virus from infecting target cells, CD4⁺ and CD8⁺ T cells perform non-redundant immunological functions directed towards the reduction of viral load after infection. CD8⁺ T cells detect virally infected host cells by recognizing short viral sequences (called epitopes) derived from the different viral proteins synthesized within the host cells and presented by the major histocompatibility complex (MHC)-class I molecules. CD4⁺ T cells can also recognize and directly lyse virus-infected cells (Heller et al., 2006) but are mainly activated by epitopes derived from the processing of viral proteins internalized by uninfected professional antigen-presenting cells (mainly dendritic cells or other myeloid-lineage cells) and presented by the MHC-class II molecules. CD4⁺ T cells are not only involved in the direct recognition of virus-infected cells, but also promote antibody maturation, sustain CD8⁺ T cell function and release cytokines like IFN- γ that can have direct anti-viral effects.

It is important to highlight that the presentation of viral epitopes by MHC-class I or II molecules is not dependent on the location of the viral proteins within the virions, but by other parameters such as the kinetics and quantity of the viral protein synthesized within the infected cells. This means that spike-specific T cells are not more efficient than nucleoprotein-specific T cells in recognizing virus-infected cells or even in helping anti-spike specific antibody production. We have tried to explain such concepts in a recent review (Bertoletti et al., 2022) and these concepts are the basis of why we embarked on a detailed analysis of CD4⁺ and CD8⁺ T cell response elicited by inactivated vaccines in comparison to mRNA vaccines. This work has been recently published in *Cell Reports Medicine* (Lim et al., 2022).

Since T cells specific for different viral proteins can have excellent protective effects against disease, our focus was to understand whether inactivated virus vaccines, comprising all the structural viral proteins present in the virions, can elicit a T cell response not only against spike

* Corresponding author.

E-mail address: antonio@duke-nus.edu.sg (A. Bertoletti).

but also other distinct structural SARS-CoV-2 proteins (membrane and nucleoprotein). We were also interested in determining whether the combined magnitude of T cells specific for spike, membrane and nucleoprotein elicited by the inactivated vaccines were comparable to the sole spike-specific T cell response elicited by the spike mRNA vaccines.

Through a comparative analysis of SARS-CoV-2-specific T cells in healthy individuals vaccinated with inactivated SARS-CoV-2 or mRNA vaccines, we showed that in line with the lower humoral immunogenicity against spike, inactivated SARS-CoV-2 vaccines induced a lower magnitude of spike-specific T cell response compared to spike mRNA vaccination. However, the lower magnitude of spike-specific T cell response was compensated by the induction of T cell response specific for membrane and nucleoprotein, the other structural proteins present in inactivated SARS-CoV-2 vaccines. This has led to a comparable magnitude of the combined inactivated vaccine-induced T cell response (spike-, membrane- and nucleoprotein-specific) to that stimulated by spike mRNA vaccines (spike-specific only), with the added theoretical advantage that a T cell response against different epitopes located in multiple viral antigens could better tolerate the viral mutations present in the new SARS-CoV-2 lineages. It is important to note that although the impact of amino acid mutations in spike protein is often well tolerated by spike-specific T cells (Gao et al., 2022; Keeton et al., 2022; Liu J. et al., 2022; Tarke et al., 2022), ~10% of spike mRNA vaccines have spike-specific T cells that are profoundly inhibited by the spike mutations detected in Omicron lineages (Naranbhai et al., 2022).

In addition to these quantitative aspects, we also detected important qualitative differences in the T cell response induced by spike mRNA and inactivated SARS-CoV-2 vaccines. While spike mRNA vaccines stimulated a coordinated spike-specific CD4⁺ and CD8⁺ T cell response, the multi-antigenic T cell response induced by inactivated SARS-CoV-2 vaccines was mediated by the selective priming of CD4⁺ T cells. The reduced ability of “protein-based” vaccines to elicit CD8⁺ T cells has been also observed in a recent published work on the immunogenicity of the spike protein-based vaccine (NVX-CoV2373) (Rydzynski Moderbacher et al., 2022). Similar to our data, the authors showed that NVX-CoV2373 elicited robust Th1 and T follicular helper CD4⁺ T cell responses but a very limited CD8⁺ T cell response, even when quantified through the expression of activation markers by flow cytometry, a technique that we have shown in our work to overestimate the presence of vaccine-specific CD8⁺ T cells.

It is challenging to define the impact of the lack of CD8⁺ T cell induction by SARS-CoV-2 inactivated vaccine on its efficacy, but several lines of evidence in animals support the sufficiency of virus-specific CD4⁺

T cells in controlling viral disease. The induction of CD4⁺ T cells specific for the nucleoprotein of SARS-CoV in the nasal cavity of mice protected the animal from lethal disease after infection with different coronaviruses (Zhao et al., 2016). Similarly, memory CD4⁺ T cells also directly and indirectly mediated protective effects in influenza A virus infected mice (Mckinsty et al., 2012). Furthermore, CD4⁺ T cells were shown to be necessary for the effective induction of local immunity in the mucosal/olfactory tissues that prevents neuroinvasion following nasal vesicular stomatitis virus infection in mice (Wellford et al., 2022).

It is therefore possible that the multi-antigenic CD4⁺ T cell response induced by inactivated virus vaccine (spike-, membrane- and nucleoprotein-specific) might be equally protective in ameliorating COVID-19 severity when compared to the mono-antigenic (spike) coordinated CD8⁺ and CD4⁺ T cell response induced by spike-based mRNA vaccination (Fig. 1). Recent clinical data from Hong Kong measuring the protective efficacy against mild and severe COVID-19 in healthy adults infected with Omicron showed similar efficacy between spike mRNA and inactivated SARS-CoV-2 virus vaccine preparations after three doses (Mcmenamin et al., 2022). This observation suggests that both the lack of the coordinated activation of CD4⁺ and CD8⁺ T cells and lower ability to induce neutralising antibodies observed in inactivated virus vaccine recipients can be compensated by the multi-antigenic nature of the CD4⁺ T cell response that could better tolerate the mutations present in Omicron.

Our study also showed that the level of multi-specific CD4⁺ T cell responses remained stable six months after vaccination and did not wane significantly unlike antibody titers. On the other hand, a third dose of inactivated vaccine did increase antibody levels but had negligible effect on the frequency of CD4⁺ T cells. Longitudinal studies will therefore be necessary to evaluate the persistence of such multi-specific CD4⁺ T cell response after inactivated virus vaccination, even though cellular immunity has been shown to be much more stable overtime than antibody levels both after other vaccination and natural infection (Le Bert et al., 2020; Dan et al., 2021). Furthermore, our data also show that heterologous vaccination with mRNA vaccine and inactivated virus vaccines induce SARS-CoV-2 multi-antigenic specific CD4⁺ and spike-specific CD8⁺ T cells, reaffirming that heterologous vaccination with different preparations could be a feasible strategy for possible long term protection (Cerqueira-Silva et al., 2022; Khoo et al., 2022).

In our opinion, the changing landscape of the SARS-CoV-2 pandemic with the emergence of novel lineages that can easily escape the protective ability of antibodies have prompted a re-evaluation of what inactivated SARS-CoV-2 vaccines can do. We believe that vaccine efficacy should no longer be evaluated solely by its ability to prevent infection,




Fig. 1. Characteristics of spike mRNA and inactivated SARS-CoV-2 vaccine-induced T cell response. NP, nucleoprotein; Mem, membrane.

but also by its capability to protect from the development of severe disease. From this perspective, it does not seem wise to relegate inactivated virus vaccines to an inferior league based only on the assessment of humoral immunity response. It would be more prudent to understand how the superior breadth of the vaccine T cell response can represent a real long term protective asset and as such be utilised in this long drawn battle against COVID-19.

Footnotes

This publication was supported by the Singapore Ministry of Health's National Medical Research Council MOH-000019 (MOH-StaR17Nov-0001) grant. A. Bertoletti and A.T. Tan reported a patent for a method to monitor SARS-CoV-2-specific T cells in biological samples pending and are the co-founders of T Cell Diagnostic (TCD) Pte Ltd. J. M. E. Lim declares no conflict of interest.

References

- Bertoletti, A., Le Bert, N., Tan, A.T., 2022. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. *Immunity* 55, 1764–1778.
- Cerqueira-Silva, T., Katikireddi, S.V., De Araujo Oliveira, V., Flores-Ortiz, R., Junior, J.B., Paixao, E.S., Robertson, C., Penna, G.O., Werneck, G.L., Barreto, M.L., Pearce, N., Sheikh, A., Barral-Netto, M., Boaventura, V.S., 2022. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. *Nat. Med.* 28, 838–843.
- Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.L., Haupt, S., Frazier, A., Nakao, C., Rayaprolu, V., Rawlings, S.A., Peters, B., Krammer, F., Simon, V., Saphire, E.O., Smith, D.M., Weiskopf, D., Sette, A., Crotty, S., 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 371, eabf4063.
- Gao, Y., Cai, C., Grifoni, A., Muller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Osterborg, A., Bergman, P., Chen, P., Olsson, A., Sandberg, J.K., Weiskopf, D., Price, D.A., Ljunggren, H.G., Karlsson, A.C., Sette, A., Aleman, S., Buggert, M., 2022. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat. Med.* 28, 472–476.
- Heller, K.N., Gurer, C., Munz, C., 2006. Virus-specific CD4+ T cells: ready for direct attack. *J. Exp. Med.* 203, 805–808.
- Jara, A., Undurraga, E.A., Gonzalez, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suarez, P., Garcia-Escorza, H., Araos, R., 2021. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. *N. Engl. J. Med.* 385, 875–884.
- Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., Madzorera, S.V., Moyo-Gwete, T., Mennen, M., Skelem, S., Adriaanse, M., Mutithu, D., Aremu, O., Stek, C., Du Bruyn, E., Van Der Mescht, M.A., De Beer, Z., De Villiers, T.R., Bodenstein, A., Van Den Berg, G., Mendes, A., Strydom, A., Venter, M., Giandhari, J., Naidoo, Y., Pillay, S., Tegally, H., Grifoni, A., Weiskopf, D., Sette, A., Wilkinson, R.J., De Oliveira, T., Bekker, L.G., Gray, G., Ueckermann, V., Rossouw, T., Boswell, M.T., Bhiman, J.N., Moore, P.L., Sigal, A., Ntusi, N.A.B., Burgers, W.A., Riou, C., 2022. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature* 603, 488–492.
- Khoo, N.K.H., Lim, J.M.E., Gill, U.S., De Alwis, R., Tan, N., Toh, J.Z.N., Abbott, J.E., Usai, C., Ooi, E.E., Low, J.G.H., Le Bert, N., Kennedy, P.T.F., Bertoletti, A., 2022. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. *Med (N Y)* 3, 104–118 e104.
- Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., Chia, W.N., Chen, M.I., Wang, L.F., Ooi, E.E., Kalimuddin, S., Tambyah, P.A., Low, J.G., Tan, Y.J., Bertoletti, A., 2020. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* 584, 457–462.
- Lim, J.M.E., Hang, S.K., Hariharaputran, S., Chia, A., Tan, N., Lee, E.S., Chng, E., Lim, P.L., Young, B.E., Lye, D.C., Le Bert, N., Bertoletti, A., Tan, A.T., 2022. A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. *Cell Rep. Med.* 3, 100793.
- Lim, W.W., Mak, L., Leung, G.M., Cowling, B.J., Peiris, M., 2021. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. *Lancet Microbe* 2, e423.
- Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K., Sciacca, M., Vanwyk, H., Wu, C., Yu, J., Collier, A.Y., Barouch, D.H., 2022. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. *Nature* 603, 493–496.
- Liu, L., Iketani, S., Guo, Y., Chan, J.F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M.S., Yu, J., Chik, K.K., Yuen, T.T., Yoon, C., To, K.K., Chen, H., Yin, M.T., Sobieszczyk, M.E., Huang, Y., Wang, H.H., Sheng, Z., Yuen, K.Y., Ho, D.D., 2022. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* 602, 676–681.
- Mallapaty, S., 2021. China's COVID vaccines have been crucial - now immunity is waning. *Nature* 598, 398–399.
- Mckinstry, K.K., Strutt, T.M., Kuang, Y., Brown, D.M., Sell, S., Dutton, R.W., Swain, S.L., 2012. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. *J. Clin. Invest.* 122, 2847–2856.
- Mcmenam, M.E., Nealon, J., Lin, Y., Wong, J.Y., Cheung, J.K., Lau, E.H.Y., Wu, P., Leung, G.M., Cowling, B.J., 2022. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. *Lancet Infect. Dis.* 22, 1435–1443.
- Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., Tano-Menka, R., Ofoman, O., Gayton, A., Senjobe, F., Zhao, Z., St Denis, K.J., Lam, E.C., Carrington, M., Garcia-Beltran, W.F., Balazs, A.B., Walker, B.D., Iafate, A.J., Gaiha, G.D., 2022. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. *Cell* 185, 1041–1051 e1046.
- Peng, Q.L., Zhou, R.H., Wang, Y.W., Zhao, M.Q., Liu, N., Li, S., Huang, H.D., Yang, D.W., Au, K.K., Wang, H., Man, K., Yuen, K.Y., Chen, Z.W., 2022. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. *EBioMedicine* 77, 103904.
- Rydzynski Moderbacher, C., Kim, C., Mateus, J., Plested, J., Zhu, M., Cloney-Clark, S., Weiskopf, D., Sette, A., Fries, L., Glenn, G., Crotty, S., 2022. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. *J. Clin. Invest.* 132, e160898.
- Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin, B., Phillips, E., Mallal, S., Sidney, J., Filaci, G., Weiskopf, D., Da Silva Antunes, R., Crotty, S., Grifoni, A., Sette, A., 2022. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* 185, 847–859 e811.
- Thomas, S.J., Moreira Jr., E.D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G., Polack, F.P., Zerbini, C., Bailey, R., Swanson, K.A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W.V., Cooper, D., Frenck Jr., R.W., Hammit, L.L., Tureci, O., Nell, H., Schaefer, A., Unal, S., Yang, Q., Liberator, P., Tresnan, D.B., Mather, S., Dormitzer, P.R., Sahin, U., Gruber, W.C., Jansen, K.U., Group, C.C.T., 2021. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N. Engl. J. Med.* 385, 1761–1773.
- Van Dorp, L., Houldcroft, C.J., Richard, D., Balloux, F., 2021. COVID-19, the first pandemic in the post-genomic era. *Curr Opin Virol* 50, 40–48.
- Wellford, S.A., Moseman, A.P., Dao, K., Wright, K.E., Chen, A., Plevin, J.E., Liao, T.C., Mehta, N., Moseman, E.A., 2022. Mucosal plasma cells are required to protect the upper airway and brain from infection. *Immunity*. <https://doi.org/10.1016/j.immuni.2022.08.017>.
- Zhang, H., Jia, Y., Ji, Y., Cong, X., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., Wang, W., Fei, R., Liu, F., Lu, F., Chen, H., Rao, H., 2022. Inactivated vaccines against SARS-CoV-2: neutralizing antibody titers in vaccine recipients. *Front. Microbiol.* 13, 816778.
- Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Galvez, R.I., Cortes, F.H., Grifoni, A., Tarke, A., Chang, J., Escarrega, E.A., Kim, C., Goodwin, B., Bloom, N.I., Frazier, A., Weiskopf, D., Sette, A., Crotty, S., 2022. Humoral and cellular immune memory to four COVID-19 vaccines. *Cell* 185, 2434–2451 e2417.
- Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K., Agnihothram, S., Baric, R.S., David, C.S., Perlman, S., 2016. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. *Immunity* 44, 1379–1391.